Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing ...
Adding sotatercept to standard therapy within a year of diagnosis lowers the risk for clinical worsening in patients with ...
Yutrepia was well tolerated and improved 6-minute walk distance and cardiac effort at 16 weeks in patients with pulmonary ...
Sotatercept (Winrevair) represents the first new mechanism of action for pulmonary arterial hypertension (PAH) treatment in over a decade, offering hope for patients with this life-threatening ...
Charles Burger, MD: Pulmonary hypertension really refers to a state where the right heart is generating high pressures to circulate the blood through the lung. Pulmonary arterial hypertension is a ...
The U.S. Food and Drug Administration (FDA) approved sotatercept in March 2024 for treatment of pulmonary hypertension, according to the drug’s maker Merck. The drug is sold under the brand name ...
The Norwood procedure for hypoplastic left heart syndrome is one of the most complex neonatal surgeries. Even after ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. This is something I'm particularly ...
This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello and welcome to this Medscape InDiscussion on pulmonary arterial hypertension (PAH). Our topic today is the very important ...
The placement of a Swan-Ganz catheter allows specialists to diagnose or test for major heart issues without requiring you to undergo major surgery. Usually, it’s a diagnostic tool for people in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback